These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11829 related articles for article (PubMed ID: 12444803)

  • 21. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
    Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
    Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines for melanoma: translating basic immunology into new therapies.
    Wolchok JD; Livingston PO
    Lancet Oncol; 2001 Apr; 2(4):205-11. PubMed ID: 11905765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
    Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
    J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA; Mossman S; Nairn N; Cheever MA
    Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine Strategy in Melanoma.
    Kwak M; Leick KM; Melssen MM; Slingluff CL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):337-351. PubMed ID: 31079792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel immunologic approaches to the management of malignant melanoma.
    Weber JS; Aparicio A
    Curr Opin Oncol; 2001 Mar; 13(2):124-8. PubMed ID: 11224710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
    Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
    J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on vaccines for high-risk melanoma.
    Weiss SA; Chandra S; Pavlick AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):269-80. PubMed ID: 24788575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine therapy for patients with melanoma.
    Haigh PI; Difronzo LA; Gammon G; Morton DL
    Oncology (Williston Park); 1999 Nov; 13(11):1561-74; discussion 1574 passim. PubMed ID: 10581603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.
    Agarwala SS; O'Day SJ
    Cancer Treat Rev; 2011 Apr; 37(2):133-42. PubMed ID: 20638184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
    Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
    Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
    Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
    Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma vaccines.
    Perales MA; Wolchok JD
    Cancer Invest; 2002; 20(7-8):1012-26. PubMed ID: 12449735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
    Hsueh EC; Gupta RK; Qi K; Morton DL
    J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 592.